Becton Dickinson and Co Stock Research

Market Summary

USD241.12-0.65

Market Closed

-0.27%

BDX Stock Price

BDX RSI Chart

BDX Valuation

Market Cap

71.3B

Price/Earnings (Trailing)

44.09

Price/Sales (Trailing)

3.79

EV/EBITDA

15.66

Price/Free Cashflow

72.01

BDX Price/Sales (Trailing)

BDX Profitability

EBT Margin

9.20%

Return on Equity

6.32%

Return on Assets

3.03%

Free Cashflow Yield

1.39%

BDX Fundamentals

BDX Revenue

Revenue (TTM)

18.8B

Revenue Y/Y

-3.79%

Revenue Q/Q

5.12%

BDX Earnings

Earnings (TTM)

1.6B

Earnings Y/Y

1.32%

Earnings Q/Q

-9.63%

Price Action

52 Week Range

214.27266.70

(Low)(High)

Last 7 days

-4.3%

Last 30 days

-6.7%

Last 90 days

1.7%

Trailing 12 Months

-3.1%

BDX Financial Health

Current Ratio

1.07

BDX Investor Care

Dividend Yield

1.49%

Dividend/Share (TTM)

3.59

Buy Backs (1Y)

2.66%

Diluted EPS (TTM)

5.34

Peers (Alternatives to Becton Dickinson and)

View All Peers In Detail

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
SYK	110.8B	19.0B	-8.78%	16.43%	46.98	6.01	8.73%	30.37%
ISRG	107.5B	6.4B	4.05%	37.44%	81.96	16.72	8.89%	-20.19%
BSX	74.1B	13.0B	-0.08%	27.20%	106.12	5.84	7.26%	-32.95%
BDX	71.3B	18.8B	-6.73%	-3.13%	44.09	3.79	-1.96%	-15.83%
EW	49.7B	5.5B	-6.18%	-16.80%	33.38	9.03	2.68%	-3.23%
MID-CAP
SWAV	7.2T	557.2M	-1.64%	66.40%	82.2K	16.8K	86.42%	730.06%
PEN	11.7B	884.6M	7.85%	115.97%	1.8K	13.2	13.08%	200.12%
GMED	5.9B	1.1B	-8.20%	-19.98%	34.14	5.75	11.20%	53.04%
IRTC	3.6B	430.0M	-11.89%	-12.63%	-34.73	8.45	26.13%	15.73%
TNDM	1.7B	794.7M	-29.15%	-60.56%	-8.43	2.16	7.73%	-3556.34%
SMALL-CAP
ATEC	1.6B	389.0M	-3.76%	82.19%	-10.63	4.18	44.08%	6.96%
SILK	1.2B	150.7M	-30.80%	0.49%	-21.65	7.87	40.31%	1.80%
AVNS	1.1B	814.3M	-20.14%	-16.22%	24.47	1.34	6.96%	121.89%
CSII	839.3M	239.8M	0.70%	0.15%	-22.16	3.5	-4.74%	-31.15%

Financials for Becton Dickinson and

* denotes actual numbers (not divided by Millions)
Income Statement (Last 12 Months)					(In Millions)
Description	(%) Q/Q	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1
Revenue	-1.0%	18,809	18,999	18,870	19,219	19,185
S&GA Expenses	-0.6%	4,723	4,750	4,709	4,851	4,902
R&D Expenses	-0.5%	1,265	1,271	1,256	1,340	1,355
Costs and Expenses	-1.0%	16,570	16,736	16,588	16,959	16,969
EBITDA	-0.2%	4,403	4,410	5,052	5,026	-
EBITDA Margin	-0.8%	0.23*	0.23*	0.25*	0.24*	-
Earnings Before Taxes	0.2%	1,751	1,747	1,783	1,697	1,654
EBT Margin	-2.7%	0.09*	0.09*	0.11*	0.11*	-
Interest Expenses	4.2%	423	406	398	409	425
Net Income	0.4%	1,617	1,611	1,779	1,756	1,921
Net Income Margin	-10.1%	0.08*	0.09*	0.09*	0.09*	-
Free Cahsflow	-10.4%	1,342	1,498	1,326	1,897	-

Balance Sheet					(In Millions)
Description	(%) Q/Q	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1
Assets	2.4%	54,394	53,129	52,934	53,199	54,786
Current Assets	17.3%	9,587	8,175	8,141	9,547	10,152
Cash Equivalents	237.9%	2,068	612	1,006	2,558	3,147
Inventory	1.4%	3,656	3,604	3,224	3,163	3,258
Net PPE	1.7%	6,356	6,247	6,012	6,005	6,406
Goodwill	0.1%	24,780	24,763	24,621	23,968	24,096
Current Liabilities	-4.2%	7,304	7,625	7,811	7,080	6,657
LT Debt, Non Current	12.2%	16,010	14,268	13,886	14,683	17,584
Shareholder's Equity	0.9%	25,689	25,472	25,282	25,493	24,525
Retained Earnings	1.2%	15,563	15,384	15,157	15,088	14,416
Additional Paid-In Capital	0.3%	19,639	19,590	19,553	19,511	19,495
Accumulated Depreciation	2.5%	6,848	6,679	6,402	6,399	6,788
Shares Outstanding	0.0%	285	285	-	-	-

Cashflow (Last 12 Months)					(In Millions)
Description	(%) Q/Q	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1
Cashflow From Operations	-17.2%	1,937	2,340	2,471	2,339	2,523
Share Based Compensation	-1.2%	238	241	233	231	231
Cashflow From Investing	2.7%	-2,754	-2,829	-3,220	-1,896	-1,970
Cashflow From Financing	-28.1%	-943	-736	-1,329	-1,609	-
Dividend Payments	1.1%	1,104	1,092	1,082	1,071	1,061
Buy Backs	-83.3%	500	3,000	-	-	-

Risks for BDX

What is the probability of a big loss on BDX?

27.3%

Probability that Becton Dickinson and stock will be more than 20% underwater in next one year

Probability that Becton Dickinson and stock will be more than 30% underwater in next one year.

Probability that Becton Dickinson and stock will be more than 40% underwater in next one year.

*Calculated based on probability distribution of losses observed in actual data in the last 5 years.

How does BDX drawdown profile look like?

Y-axis is the maximum loss one would have experienced if Becton Dickinson and was unfortunately bought at previous high price.

Drawdowns

Returns for BDX

Cumulative Returns on BDX

10.9%

10-Year Cumulative Returns

7.2%

7-Year Cumulative Returns

3.4%

5-Year Cumulative Returns

3.4%

3-Year Cumulative Returns

What are the long-term rolling returns for BDX?

FIve years rolling returns for Becton Dickinson and.

Annualized Returns

Which funds bought or sold BDX recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
2023-05-24	Old North State Trust, LLC	unchanged	-	-8,000	310,000	0.22%
2023-05-23	MOUNTAIN PACIFIC INVESTMENT ADVISERS INC/ID	reduced	-0.87	-46,271	1,275,330	0.09%
2023-05-23	Front Row Advisors LLC	added	0.97	-	26,000	0.01%
2023-05-23	Toroso Investments, LLC	added	111	2,068,000	4,012,000	0.07%
2023-05-23	Brookfield Corp /ON/	new	-	7,885,390	7,885,390	0.03%
2023-05-22	AMERIPRISE FINANCIAL INC	reduced	-	-23,097,900	844,442,000	0.28%
2023-05-22	Arete Wealth Advisors, LLC	sold off	-100	-287,030,000	-	-%
2023-05-22	FDx Advisors, Inc.	unchanged	-	-	1,667,000	0.07%
2023-05-22	PUTNAM INVESTMENTS LLC	added	8.87	417,290	7,403,670	0.01%
2023-05-22	AMERIPRISE FINANCIAL INC	reduced	-41.79	-22,921,000	31,488,000	0.01%

Latest Funds Activity

Are funds buying BDX calls or puts?

Calls

Puts

Are funds bullish or bearish(Calls - Puts)?

Net Call Options

No. of funds that own BDX

No. of Funds

Becton Dickinson and News

Schedule 13G FIlings of Becton Dickinson and

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 14, 2023	price t rowe associates inc /md/	6.7%	18,962,386	SC 13G/A
Feb 09, 2023	vanguard group inc	8.94%	25,421,347	SC 13G/A
Feb 07, 2023	blackrock inc.	8.4%	23,781,609	SC 13G/A
Feb 14, 2022	price t rowe associates inc /md/	7.0%	20,016,331	SC 13G
Feb 09, 2022	vanguard group inc	8.48%	24,176,366	SC 13G/A
Feb 08, 2022	blackrock inc.	7.5%	21,348,508	SC 13G/A
Feb 16, 2021	price t rowe associates inc /md/	4.2%	12,347,992	SC 13G/A
Feb 10, 2021	vanguard group inc	8.38%	24,360,444	SC 13G/A
Feb 08, 2021	fmr llc	-	0	SC 13G/A
Feb 05, 2021	blackrock inc.	7.9%	22,926,497	SC 13G/A

BDX Fair Value

Recent SEC filings of Becton Dickinson and

View All Filings

Date Filed	Form Type	Document
May 25, 2023	SD	SD
May 24, 2023	25-NSE	25-NSE
May 08, 2023	4	Insider Trading
May 08, 2023	4	Insider Trading
May 04, 2023	8-K	Current Report
May 04, 2023	10-Q	Quarterly Report
May 02, 2023	4	Insider Trading
Apr 21, 2023	144	Notice of Insider Sale Intent
Apr 17, 2023	144	Notice of Insider Sale Intent
Apr 06, 2023	4	Insider Trading

Latest Insider Trading transactions for BDX

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
2023-05-01	Quinn Michelle	sold (taxes)	-	-	-99.00	evp and general counsel
2023-04-04	Neal Shana Carol	acquired	-	-	8,229	chief human resources officer
2023-04-04	Neal Shana Carol	sold (taxes)	-	-	-731	chief human resources officer
2023-03-02	Ezell Antoine C	sold (taxes)	-	-	-650	evp, president na & cmo
2023-03-01	Spoerel Thomas J	sold (taxes)	-	-	-35.00	svp,controller&chief acct off
2023-03-01	Garrison Michael David	sold (taxes)	-	-	-193	evp & president medical
2023-03-01	Ezell Antoine C	sold (taxes)	-	-	-418	evp, president na & cmo
2023-02-03	Byrd Richard	sold	-353,261	248	-1,421	evp & president interventional
2023-01-26	Fraser Claire	acquired	-	-	848	-
2023-01-24	LARSEN MARSHALL O	acquired	-	-	848	-

About Becton Dickinson and

Thomas E. Polen

www.bd.com

65535

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company's BD Medical segment offers peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detections, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, and sharps disposal systems; IV medication and infusion therapy delivery systems, medication compounding workflow systems, automated medication dispensing and supply management systems, and medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes; and prefillable drug delivery systems. Its BD Life Sciences segment provides specimen and blood collection products; automated blood and tuberculosis culturing, molecular testing, microorganism identification and drug susceptibility, and liquid-based cytology systems, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent systems, and solutions for single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. The company's BD Interventional segment offers hernia and soft tissue repair, biological and bioresorbable grafts, biosurgery, and other surgical products; surgical infection prevention, surgical and laparoscopic instrumentation products; peripheral intervention products; and urology and critical care products. The company was founded in 1897 and is based in Franklin Lakes, New Jersey.

BDX Income Statement

2023-03-31

Condensed Consolidated Statements of Income - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Mar. 31, 2023	Mar. 31, 2022	Mar. 31, 2023	Mar. 31, 2022
Income Statement [Abstract]
Revenues	$ 4,821	$ 4,750	$ 9,407	$ 9,468
Cost of products sold	2,586	2,637	5,038	5,135
Selling and administrative expense	1,205	1,192	2,392	2,378
Research and development expense	337	327	651	641
Acquisition-related integration and restructuring expense	62	28	106	62
Other operating expense (income), net	4	0	7	(4)
Total Operating Costs and Expenses	4,193	4,185	8,193	8,212
Operating Income	628	564	1,213	1,256
Interest expense	(118)	(97)	(220)	(195)
Interest income	10	2	16	4
Other income (expense), net	8	(27)	1	(24)
Income from Continuing Operations Before Income Taxes	529	442	1,009	1,041
Income tax provision	68	52	40	84
Net Income from Continuing Operations	460	390	969	958
Income from Discontinued Operations, Net of Tax	0	64	0	173
Net Income	460	454	969	1,131
Preferred stock dividends	(23)	(23)	(45)	(45)
Net income applicable to common shareholders	$ 438	$ 431	$ 924	$ 1,086
Income from Continuing Operations, Basic (USD per share)	$ 1.54	$ 1.29	$ 3.25	$ 3.20
Income from Discontinued Operations, Basic (USD per share)	0	0.22	0	0.61
Basic Earnings per Share (USD per share)	1.54	1.51	3.25	3.81
Income from Continuing Operations, Diluted (USD per share)	1.53	1.28	3.24	3.18
Income from Discontinued Operations, Diluted (USD per share)	0	0.22	0	0.60
Diluted Earnings per Share (USD per share)	1.53	1.50	3.24	3.78
Dividends per Common Share (USD per share)	$ 0.91	$ 0.87	$ 1.82	$ 1.74

BDX Balance Sheet

2023-03-31

Condensed Consolidated Balance Sheets - USD ($) $ in Millions	Mar. 31, 2023	Sep. 30, 2022
Current Assets:
Cash and equivalents	$ 1,981	$ 1,006
Restricted cash	87	153
Short-term investments	6	8
Trade receivables, net	2,413	2,191
Inventories:
Materials	788	707
Work in process	428	397
Finished products	2,441	2,120
Inventories	3,656	3,224
Prepaid expenses and other	1,444	1,559
Total Current Assets	9,587	8,141
Property, Plant and Equipment	13,204	12,415
Less allowances for depreciation and amortization	6,848	6,402
Property, Plant and Equipment, Net	6,356	6,012
Goodwill	24,780	24,621
Developed Technology, Net	8,610	9,108
Customer Relationships, Net	2,512	2,683
Other Intangibles, Net	555	519
Other Assets	1,994	1,848
Total Assets	54,394	52,934
Current Liabilities:
Current debt obligations	2,214	2,179
Payables, accrued expenses and other current liabilities	5,090	5,632
Total Current Liabilities	7,304	7,811
Long-Term Debt	16,010	13,886
Long-Term Employee Benefit Obligations	920	902
Deferred Income Taxes and Other Liabilities	4,471	5,052
Commitments and Contingencies (See Note 5)
Shareholders’ Equity
Preferred stock	2	2
Common stock — $1 par value; authorized — 640,000,000 shares; issued — 364,639,901 shares in March 31, 2023 and September 30, 2022	365	365
Capital in excess of par value	19,639	19,553
Retained earnings	15,563	15,157
Deferred compensation	24	23
Treasury stock	(8,327)	(8,330)
Accumulated other comprehensive loss	(1,575)	(1,488)
Total Shareholders’ Equity	25,689	25,282
Total Liabilities and Shareholders’ Equity	$ 54,394	$ 52,934